iShares US Healthcare Providers
How Can Changing Demographics Impact Investors?
Changing demographics impact investors in many ways. The demand for bonds could increase, putting downward pressure on yields.
Squire Study Supports Portrazza’s Approval
The FDA approved Portrazza for the treatment of squamous NSCLC based on the results of a phase III study named Squire.
Express Scripts Trades Above Its 100-Day Moving Average
Express Scripts Holdings rose 0.4%. The company was in the news on November 10 when it announced that it would remove Linden Care Pharmacy from its network.
Universal Health Services’ Behavioral Health Business in 3Q15
Universal Health Services (UHS) is expected to benefit from its leading market position in the behavioral health business in 3Q15.
Decoding Humana’s Revenue Stream in 2015
Humana reported revenues of about $54.3 billion in its 2015 results. This amounts to a 12% revenue growth in 2015, compared to ~$48.1 billion in 2014.
Danaher Corporation’s Excess Returns Fail to Impress
Earlier in this series, we looked at Danaher’s return on invested capital on a standalone basis. However, we were only looking at half the story.
Danaher’s Environmental Segment Is a Cut above the Rest
Danaher’s Environmental & Applied Solutions unit was responsible for 25% of the company’s sales in 2015.
Introducing Danaher: A Diversified Healthcare Company
Danaher is a diversified conglomerate with a market cap of ~$56 billion. Its customers are mostly professionals and organizations rather than retail consumers.
Adeptus Health Leads the Small-Cap Space with 3.6% Gain
Adeptus Health (ADPT) rose by 3.6% on November 10, 2015. The stock rose following its announcement that it had officially opened its first Texas hospital.
Inovalon Gains 2.1%, to Present at NASDAQ Investor Program
Inovalon closed at $18.26 and was trading below 20-, 50-, and 100-day moving averages.
Centene’s Hunt for New Growth Opportunities in Existing Markets
Centene believes that if all its existing markets adopt Medicaid expansion, it would result in 4 million additional members becoming eligible for Medicaid.
How Does UHS’s Valuation Compare to Other Hospital Companies?
On February 26, 2016, Universal Health Services (UHS) was trading at a forward PE (price-to-earnings) multiple of about 13.8x.
Danaher to Declare Its First Earnings after Fortive Separation
Danaher Corporation (DHR), which became a diversified healthcare company after its restructuring actions, is slated to declare its 3Q16 earnings on October 20. The consensus Wall Street estimate is for Danaher to post adjusted EPS of $0.83 on sales of ~$4.1 billion.
How Does Jacobs Engineering Look for Fiscal 2017?
In the 4Q16 earnings call, Jacobs Engineering provided its initial guidance for the adjusted EPS and a brief overview of the prevailing market conditions.
Community Health System Plummets 35.3%, IHF Lost ~6.4%
Community Health Systems (CYH) fell by 35.3% on October 22, 2015, the biggest fall of the day in the iShares US Healthcare Providers ETF’s portfolio.
Sharpe ratio shows healthcare ETFs are a strong relative investment
Adjusting performance on a risk basis As new insurees flood the insurance market and baby boomers approach retirement, the healthcare space should expect dramatic increases in demand. Alongside an increase in demand, however, has been a tightening of reimbursement policy and a more stringent regulatory environment. These variables present unique risks and opportunities for healthcare […]
United Health Group Stock Has Risen 28% in 2018
On November 29, United Health Group’s (UNH) stock price closed at $282.55, which is ~8% growth from its close of $261.62 on November 23.
Express Scripts: How Its Performance Contributed to Its Valuation
Express Scripts’ (ESRX) revenue fell 1% in both 2016 and the first nine months of 2017.
Hospital Industry Reacts to the Failed Healthcare Bill
On March 24, 2017, House Speaker Paul Ryan pulled back the American Health Care Act, also known as “Trumpcare,” before votes were cast.
How Did Danaher’s Operating Segments Fare in 4Q16?
Currently, Danaher (DHR) reports its revenue under four operating segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Why Danaher Stock Rose after Its 4Q16 Results
Danaher Corporation (DHR) announced its 4Q16 and 2016 earnings results before the market opened on January 31, 2017. Let’s take a look.
Behind Danaher’s 4Q16 Revenue Estimates
Danaher (DHR) reported ~$5.9 billion in consolidated revenue in 4Q15. Analysts expect DHR to report $4.5 billion in 4Q16 revenue.
What Factors Could Drive Danaher Stock in 2017?
Danaher Corporation (DHR) will announce its 4Q16 earning results before the market opens on January 31, 2017. What should we expect?
What Made Cepheid Attractive to Danaher?
On September 6, 2016, Danaher (DHR) announced that it has entered into a definitive agreement to acquire Cepheid (CPHD) for $4 billion.
Danaher’s Dental Unit Enjoys These Competitive Advantages
Danaher’s Dental segment is a $2.7 billion business.
How Danaher Diagnostics Fares against Its Competition
Danaher’s Diagnostics unit had operating margins of 15.4% in 2015 and 17.2% in 1H16.
The Key Product Lines That Make Up Danaher’s Diagnostics Business
Danaher’s (DHR) Diagnostics unit, established through the acquisition of Radiometer in 2004, earned $4.9 billion in sales in 2015.
How Are Danaher’s Returns Compared to Its Industry Peers’?
Danaher’s ROIC fell steadily from 15.5% in 2006 to 8.5% in 2015, indicating that it has probably had fewer high return reinvestment opportunities since then.
Why 3M Sees an Opportunity in Tier B Chinese Hospitals
20% of 3M Company’s (MMM) Healthcare sales are derived from developing economies, which have been growing organically since 2012.
How 3M Company’s Products Look After Your Health
Revenues from 3M Company’s (MMM) Healthcare segment rose from 16.7% ($5 billion) of total annual revenue in 2011 to 17.5% ($5.4 billion) in 2015.
LabCorp Trades at Discounted PE Multiples Compared with Peers in 1Q16
In a survey of 22 brokerage companies on April 26, 2016, about 71.4% of the brokers rated LabCorp (LH) a “buy,” while 28.6% rated it a “hold.” None of the brokers rated it a “sell.”
HCA Holdings’s Operating Expense Ratio Fell in 4Q15
In 4Q15, HCA Holdings spent about $8.1 billion on salaries, supplies, and other operating expenses combined—an increase of 5.3% from $7.7 billion spent in 4Q14.
IHF’s Large-Cap Stocks Gave Positive Returns
The large-cap stocks of the iShares US Healthcare Providers ETF (IHF) rose marginally with a return of 0.35%. They outperformed IHF and SPY.
IHF Sustains the Biotech Sell-off, Loses Marginally
The sell-off that took down one of the days last week weighed heavily on biotechs. The iShares US Healthcare Providers ETF (IHF) was the best-performing biotech ETF, and the SPDR S&P Biotech ETF (XBI) was the worst.
FDA Approves Eli Lilly’s Portrazza Based on Squire Study
The FDA has approved Eli Lilly’s Portrazza, the first biologic to get approval as a first-line treatment for patients with metastatic squamous NSCLC.
UnitedHealth Declares Dividend, Stock Rises
UnitedHealth Group rose 1.4% on November 10, 2015. The company announced a dividend of $0.5 per share to be paid on December 15, 2015.
Team Health Led the Mid-Cap Space with 10.1% Gains
Team Health Holdings (TMH) rose by 10.1% for the week ending October 23, 2015. The stock rose as it announced preliminary numbers for 3Q15.
What Are UnitedHealth Group’s Growth Opportunities?
To strengthen their presence in international markets, health insurance companies have been involved in mergers and acquisitions with local insurance companies in these markets.